Oxurion extends its financing program until 2027

Oxurion NV, a biopharmaceutical company based in Leuven, has signed a new amendment with Atlas Special Opportunities II, extending its convertible bond financing program until March 2, 2027. This extension adjusts the maturities of all bonds to 72 months. Atlas may transfer bonds to affiliated entities outside the United States.

The program includes bonds issued monthly for EUR 300,000, with possible increases of EUR 100,000 subject to agreement. A minimum market capitalization of EUR 500,000 and EUR 1.2 million in liquidity over 22 days are required.

FSMA approval may be required before this amendment can be implemented. Oxurion undertakes to complete the necessary formalities promptly.